IL15 and neoplasm: After 22 days of treatment (survival endpoint for mice with HBSS treated PC3 tumors), cyto-IL-15 combined with ADU led to complete tumor regression (98% volume reduction), significantly increased survival (undefined, p <0.01) compared to the HBSS treated cohort and cured 3 out of 5 mice (60%) (Figures 1I–L).